Review article

THE BLOOD IS RICH IN DIFFERENT TYPES OF MESODERM DERIVED STEM AND PROGENITOR CELLS

KOVAČEVIĆ FILOVIĆ Milica*

Faculty of Veterinary Medicine, University of Belgrade, Serbia

(Received 26 May; Accepted 3 June 2014)

The blood and bone marrow have been thoroughly investigated for more than a century, but we are still gaining surprising new informations. Blood transports different mature cells such as erythrocytes, platelets and granulocytes, but curiously, the blood is also transporting a number of non-differentiated cells of various mesodermal lineages: hematopoietic and mesenchymal stem and progenitor cells, endothelial progenitor cells and very small embryonal like cells are some of the most impressive examples. In adults the bone marrow is the source of practically all cells that could be found in the blood. Stem and progenitor cells egress from the bone marrow and home to the bone marrow or various tissues in a highly regulated manner. The fact that the hematopoietic stem and progenitor cells traffic through the blood and repopulate the bone marrow niche is largely explored in stem cell therapy in human medicine. In this review we will briefly describe the main characteristics of stem and progenitor cells, the mechanisms of their mobilization from the bone marrow and homing to target tissues. Also, the history and importance of the fact that different stem, progenitor and precursor cells could be isolated from the blood circulation will be discussed in the light of informations concerning their use in human and veterinary medicine.

Key words: peripheral blood, stem cells, progenitor cells, veterinary medicine

INTRODUCTION

Commonly identified blood cells are differentiated cells of myeloid and lymphoid lineages, produced in the bone marrow (BM) and released to perform their functions in the circulation or after migration to different tissues. Apart from differentiated cells the bone marrow also releases into the blood several mesoderm derived non-differentiated cell types. Namely, in human and animal cord and peripheral blood the presence of multipotent hematopoietic stem cells (HSC) and multiple types of

* Corresponding author: e-mail: milica@vet.bg.ac.rs
committed hematopoietic progenitor cells (HPC) including osteoclast progenitor or precursor cells (OPC) has been demonstrated. Endothelial progenitor cells (EPC) are a distinct population of mesoderm derived cells that have the ability to differentiate to endothelial cells. Although being considered as sessile, mesenchymal stromal/stem cells (MSC) and osteoprogenitor cells were also found in the blood. More curiously, cells of hematopoietic lineage, disguised in a mesenchymal mantle, called fibrocytes, are also present in the blood. The function of the listed stem and progenitor cells is versatile, but they possess similar mechanisms to enter and exit the blood. In this review we will briefly describe the main characteristics of stem and progenitor cells, mechanisms of their mobilization from the bone marrow and homing to target tissues. Also, the history and importance of the fact that they could be isolated from the blood circulation will be discussed in the light of informations concerning their use in human and veterinary medicine.

**Stem and progenitor cell characteristics**

The classical model of hierarchically organized adult cell populations implies the existence of: 1) a small number of quiescent non-differentiated multipotent stem cells; 2) a broader range of committed progenitor cells that extensively proliferate and differentiate on tissue demand and 3) a large number of mature cells. True stem cells are capable of self-renewal. They perform asymmetrical divisions producing one identical daughter cell that maintains their own population and one cell that undergoes differentiation and is destined to replenish the progenitor cell pool. Another exciting phenomenon that is largely discussed in scientific literature is stem cell plasticity. In the widest sense, plasticity describes the possibility of any cell, regardless of its state of differentiation, that with or without cell division can acquire the morphology, phenotype and/or function of another cell. For example, a morphologically non recognizable erythroid progenitor cell becomes an erythroblast and further on an erythrocyte. In terms of stem cell biology, plasticity often means that stem or progenitor cells have intra-tissue and/or inter-tissue plasticity or trans-differentiation potential. Intra-tissue plasticity refers to the transformation of lineage restricted, but not fully differentiated cells, to a cell of another tissue specificity. For example, it has been demonstrated that progenitor cells of myeloid and lymphoid lineage could trans-differentiate to each other during their developmental pathways [1,2]. The example of inter-tissue plasticity is the putative HSC potential to give rise to connective tissue cells like chondrocytes, osteoblasts and adipocytes [3] or putative MSC potential to trans-differentiate across germ layer specificity into neurons or hepatocytes [4]. The experimental evidences for stem cell plasticity mostly derive from in vitro experiments and it is precocious to consider that intra-tissue and inter-tissue plasticity is a rare event that could be triggered during different pathologies in vivo [5]. Indeed, many cases of trans-differentiation could be explained through cell fusion that occurs between
donor and damaged recipient cells in a process know as “rescuing” [5]. The other important challenge in plasticity research is matching the phenotype of isolated cells with their function. If more than one cell is transplanted, the possibility that cells have distinct differentiation potential, even with same phenotype, is present. If the issue is bone marrow or blood, the versatility of cell types is high, and these tissues are frequently reported to have multi- or pluripotent cells [3]. This brief review of stem and progenitor cell characteristics should be useful for understanding the complexity and nature of stem and progenitor cells (SPCs) found in the blood.

**Bone marrow harbor stem and progenitor cells in specific niches**

During prenatal development HSCs leave the fetal liver and spleen to colonize the bone marrow, which is the unique HSC niche during postnatal life. While residing in the fetal liver and spleen, HSCs cycle continuously and produce a large pool of hematopoietic stem and progenitor cells (HSPCs), able to repopulate the bone marrow. Long term repopulating HSCs are a small population of true stem cells that are exclusively characterized by the *in vivo* ability to repopulate the bone marrow of secondary recipients after serial transplantations, gracely to their self-renewal capacity. In adult bone marrow, during steady-state, long term repopulating HSCs divide once in 2.5 weeks in mice and cat and once in 40 weeks in humans, and this low proliferative activity is related to their life-long stemness potential [6]. HSCs quiescence and cycling activity, as well as self-renewal, differentiation, survival and migration are regulated through the contact with bone marrow stromal cells, extracellular matrix (ECM), cytokines/growth factors and physicochemical factors like pH and concentration of oxygen and Ca++ [7-9]. Beside HSCs, the bone marrow harbors an important population of MSCs that differentiate to stromal osteoblasts and adipocytes. Other niche cells are adventitial reticular cells/pericytes, endothelial cells, endothelial progenitor cells and a large number of hematopoietic progenitors and precursors that have seeded the bone marrow during the prenatal development (Figure 1). Some of ligand/receptor complexes that provide the maintainance of HSC inducing their quiescence are Angiopoietin/Tie-1, Stem Cell Factor/c-kit, MPL/Thrombopoietin and TGF-β/TGF-βR. Self-renewal is promoted through Notch signaling. HSC, EPC, MSC and fibrocyte mobilization from the bone marrow and homing to the bone marrow or other tissues in a regulated manner is organized through a complex network of adhesion and signaling molecules [9,10].
Mobilization and homing of stem and progenitor cells

Mobilization is a process of SPCs egress from their tissue niche to the blood (Figure 2). Homing is a mechanism by which SPCs circulating in the blood enter the connective tissue of specific organs, while engraftment is homing with restoration of specific cell functions. In the steady-state, HSPCs re-enter bone marrow, but the destiny of mesenchymal stem/progenitor cells (MSPCs) and other SPCs is not clear yet. During tissue injury, all mobilized cells are recruited to the sites of inflammation [10].

The current view is that the most important axe in the SPCs mobilization and homing is the balance between Stromal Derived Factor-1 (SDF-1), a small chemokine predominantly syntetized by fibroblasts and osteoblasts in the bone marrow, and bioactive lipid Sphingosine 1-Phosphate (S1-P) released mainly by blood components [11]. During stress reactions the level of SDF-1 decreases and that of S1-P increases, favoring SPC mobilisation. The major SDF-1 receptor is CXCR4, a molecule expressed on different bone marrow stromal cells including all types of SPCs [11]. The receptor for S1-P is S1-P1 [11]. SDF-1 level in the bone marrow, as well as number of HSPCs in the circulation are inversely related and have a circadian rhythm governed through noradrenaline secretion by the sympathetic nervous system and thus HSPC number in the peripheral blood peaks 5 h after the initiation of light and reaches a nadir 5 h after
darkness [9]. Other molecular complexes that influence SPCs mobilization and homing are the very late cell adhesion molecule 4 (VLA-4) on stem cells and the vascular cell adhesion protein 1 (VCAM-1/CD106) on pericytes and endothelial cells [12]. Stem cell factor, erythropoietin, stress and exercise also mobilize different SPCs and the significance of these findings remains to be determined. The recent discovery that reduction of endogenous prostaglandin E2 levels with NSAID augments the number of HSPCs in the circulation, should be of great clinical interest [13].

Inflammation and stress modulate the responsiveness of all cells and tissues and up-regulate many signaling molecules. Pro-inflammatory cytokines like granulocyte colony stimulating factor (G-CSF), granulocyte-monocyte colony stimulating factor (GM-CSF), IL-8 and tumor necrosis factor alfa (TNF-α) are well known mobilizing agents [12]. Some data indicate that during inflammation MSPC mobilization and homing to injured tissues is mainly governed through TGF-β action [14]. The discovery of these multiple pathways that regulate the mobilization and homing of SPCs led to introduction of successful stem cell treatments in human medicine, an issue that will be discussed later in this review.
Peripheral blood is the blood obtained from standard venepuncture sites. This term is introduced to contrast the blood obtained with bone marrow aspiration and is colloquial in HSCs transplantation. The presence of HSPCs has been proven in the peripheral blood of steady-state adult mice soon after the first big achievement in experimental hematology that used the in vivo repopulation assay to define functional stem cells properties of bone marrow cells [15,16]. Now it is clear that under steady-state, HSPCs egress into peripheral blood in a circadian rhythm governed by local sympathetic nerves sprouting the vasculature and SDF-1/S1-P axe [9]. The site of their homing without any pathological event is not so clear, but current evidence suggests that HSPCs traffic for several days through various extramedullary tissues, draining through the lymphatic circulation to reach again the blood and bone marrow [17]. Much more is known about HPSC mobilization as a consequence of different types of stress and inflammation that lead to HPSC recruitment to the sites of tissue injury [18].

Although CD34+ multipotent myeloid/lymphoid progenitor cells have been widely demonstrated in the blood of humans and different animals, the first experimental evidence for the presence of long-term repopulating HSCs within human steady-state peripheral blood CD34+ cells is enabled with the use of leukoreduction filters that concentrate mononuclear cells from the blood [19]. Several years ago, in soldiers that received blood transfusions during World War II and in Vietnam War, the existence of long-term repopulating HSC in adult steady-state peripheral blood was proved, by donor type microhimerism [20]. The physiologic significance of long-term repopulating HSCs circulating through the blood in the steady-state condition is not known, but maintenance of HSCs pool in all active sites of hematopoiesis could be one of the explanations.

One of the obvious physiological reasons for progenitor cell egress from the bone marrow is the case of lymphoid lineage. Lymphoid-specified multipotent progenitors primed for T lineage, constantly leave the bone marrow and replenish the thymus in a life long need for T lymphocyte development [1]. Different maturational stages of B lymphocytes and dendritic cells also leave the bone marrow and traffic to different secondary lymphatic organs and target tissues maintaining immunity indispensable for animal/human survival [2].

The number, phenotype and functional characteristics of myeloid progenitors in the peripheral blood are described in many animal species and humans, but they are still the focus of intensive research. This is mainly due to their putative role in the pathogenesis of various disease and escalating interest in HSPC plasticity. Myeloid progenitors could be demonstrated in vitro using semisolid media and adequate growth factors. Colony forming unit – granulocyte/monocyte (CFU-GM) is a myeloid progenitor cell that forms large colonies of granulocytes and monocytes and is found
in the bone marrow and peripheral blood. One CFU-GM isolated from pig peripheral blood is presented on Figure 3a. Although the number of CFU-GM in the peripheral blood is small in steady state condition [21], pro-inflammatory molecules enhance proliferation, differentiation and maturation of bone marrow CFU-GM and rapid mobilization of these cells to the peripheral blood [18]. Mobilized CFU-GM could be recruited to the sites of inflammation in large numbers. For example, after infection with Schistostoma mansoni, thousands of eggs fluid the liver periportal venous radiculi and induce the formation of granulomas that become a place of active myelopoiesis [22]. After an experimental infection with the mentioned parasite, the number of myeloid progenitors in the whole liver was equivalent to half of their content in the femur [22]. Also, myeloid progenitors home to sites of allergic reaction and it is proposed that stimulation with local cytokine milieux influence their differentiation in situ to eosinophiles and basophilis [18]. Although all initial studies leading to the discovery of bone marrow HSPCs have been done in canines, no studies on dogs, or other large animals, have been done concerning the role of myeloid progenitors in different pathologies.

The number of steady-state erythroid progenitors in the peripheral blood, estimated in pigs, is around a hundred times lower than the number of these progenitors in the bone marrow [23] and their proliferative activity is lower comparing to counterparts in the bone marrow indicating on the possibility that the cell cycle status influences their migration/mobilization possibilities [24]. Massive mobilization of erythroid progenitors from the bone marrow is stimulated in hemolitic or hemorrhagic anemia [25], as well as in different types of myeloproliferative disorders [26] that are also connected with extramedullary, i.e. splenic, erythropoiesis [27]. Although it seems logical that mobilized erythroid progenitors would home to the spleen and other organs.

Figure 3. Peripheral blood mononuclear cells were seeded on semi-solid medium (methylcellulose) with combination of growth factors. After 10 days of cultivation (5% CO2, 37°C), committed progenitors named Colony Forming Unit – Granulocyte Monocyte (CFU-GM) formed colonies of several hundreds myeloblasts (a). Committed progenitors named Burst Forming Unit – Erythroid (BFU-E) formed colonies of several thousands of hemoglobinized erythroblasts (b). Magnification 4x.
with a microenvironment permissive for hematopoiesis/erythropoiesis, experimental evidence in mice point to the existence of particular self-renewing spleen erythroid progenitor clones, that rapidly respond to the stimulus with a fast proliferation and maturation toward erythrocytes [28]. The importance of erythroid progenitor mobilization to the peripheral blood remains to be delineated. Morphology of Burst Forming Unit – Erythroid (BFU-E) colony representative for erythroid progenitor lineage is presented on Figure 3b.

Megakaryocyte progenitor cells were found in the peripheral blood of humans [29] but no studies have been done in large animals. The megakaryocyte progenitor number rises in the blood after mobilization with G-CSF [30]. These cells express CXCR4, the main HSPC homing receptor, meaning that they are capable of homing [30]. Bone marrow is probably the only homing tissue of megakaryocyte progenitors, albeit functional megakaryocytes could be found in the spleen and lung. The significance of megakaryocyte progenitors in the blood remains to be determined.

Circulation of HSPCs in the blood and lymphatics makes a continuum with embryonal HSPC traffic. Definitive HSCs responsible for life-long production of mature blood cells, are formed in a short time window of embryo development, lasting around 3 days in mice (day 8.5 to 12). Currently, the view that the dorsal aorta endothelial cells are the source of definitive HSCs is supported with real time capture of HSCs budding from this location and the process is defined as endothelial-to-hematopoietic transition [31]. This hemogenic endothelium derives from intra-embryonic paraaortic splanchnopleural mesoderm, which contributes to the developing dorsal aorta in the aorta gonada mesonephros (AGM) region [32]. Fetal liver, spleen, thymus and finally bone marrow have not the capability to generate HSCs, but become colonized with HSCs formed in the AGM region via circulation because they possess the microenvironment which is suitable for further HSPC expansion and maturation to different blood cell lines [33, 34]. It is interesting that transplantation studies using green fluorescent protein (GFP) labeled endothelial progenitor cells derived from the bone marrow demonstrate that donor type EPC not only take part in vasculogenesis, but also retain their hematopoietic ability in recipient mouse, supporting the view that the hemogenic endothelium is present during the entire lifespan [35].

Peripheral blood hematopoietic stem and progenitor cells are used in cell therapy

The genuine ability of HSCs to colonize/repopulate the myeloablated bone marrow and maintain life long blood formation is largely used as the principal or facultative therapy in many hematologic and non hematologic deseases in humans. The discovery that HSPCs reside in the peripheral blood led to the blood born stem cell transplantation concept that today has a history of almost 30 years of practice [36]. The number of peripheral blood HSCs in the steady-state is inadequate for therapeutic purposes. First pharmaceutical agents described to mobilize HSPCs were cyclophosphamide and
adriamycin [37]. This and later findings opened the gate for important progress is stem cell therapy enabling shifting of HSPC harvest from bone marrow to peripheral blood [36]. For the last 20 years, G-CSF was successfully used in cell therapy mobilization protocols, augmenting the HSPC yield by 60 to 100 folds in the majority of cases [38]. Some patients are designated as non-responders or “poor“ mobilizers based on a low number of peripheral blood HSPCs after G-CSF treatment [39]. The new agent that resolved the problem of „poor“ mobilizers is Plerixafor, a molecule which reversibly inhibits SDF-1 binding to CXCR4, efficiently promoting HSC mobilization [12].

In year 2011 in Europe, the majority of allogenic HSPC transplantations (73% of 13,470) and all autologous HSPC transplantations have been done using peripheral blood derived cells (99% of 18,605) [40]. Cord blood has been used in 6% of allogenic transplantation and non for autologous transplantation [40].

Recently, it was suggested that steady-state HSPC from peripheral and cord blood could be used as a starting cell population for massive in vitro production of erythrocytes available for transfusion [41] and vaccine development [42]. Moreover, after optimized in vitro expansion protocols, HSPCs isolated from the cord blood, efficiently reduced neutropenia after high dose chemotherapy [43].

Lately, several authors have considered autologous peripheral blood HSPC transplantation in dogs with T or B lymphoma [44,45]. No statistics on the usefulness of such a therapy could be done due to the low number of cases, but successful engraftment after specified protocols has been demonstrated [45]. As a result of these successful transplantations, after 60 years, the dog has finally moved from the status of large animal preclinical model for HSPC transplantation, to being treated as a patient.

Efficient management of HSPC is possible because of optimized protocols for their cryopreservation. For long term storage, temperatures in the range from -156°C to -196°C are recommended [46]. For short term storage not longer than 7 to 10 days, low oxygen and high carbon-dioxide atmosphere at 4°C are suggested [47,48].

HSPCs therapy in human medicine was developed during decades and this brief overview is written with the idea that further research in veterinary medicine is needed in order to develop specific veterinary therapies.

Blood harbors osteoclast precursor cells: exotic cells with classical function

Once thought to be a unipotent progenitor cell, Colony-Forming Unit – Macrophage (CFU-M) is now defined as a common progenitor cell for monocytes/macrophages, osteoclasts and dendritic cells [49].

The subpopulation of monocytes/macrophages with a specific phenotype, represent direct osteoclast precursor cells [50]. One of the earliest findings related to osteoclast precursor cells (OPC) was that they travel through the blood to the bone marrow area where the bone should be resorbed, settle and terminate maturation to functional cells [51]. Their maturation is regulated with osteoblast secreted factors: Macrophage
Colony Stimulating Factor (M-CSF), RANKL and osteoprotegerin [52]. SDF-1 and S1-P are suggested to play a role in OPC egress and homing during steady-state in mice [53]. The presence of OPC in the cord and peripheral blood could be demonstrated in vitro. OPCs are adherent cells with fibroblast-like morphology that give rise to multinucleated osteoclasts that have tartrate-resistant acid phosphatase (TRAP) activity and express CD45 (pan-leukocyte marker) and CD51/CD61 [54]. It was also demonstrated that the number of osteoclasts in the peripheral blood is increased in patients with erosive osteoarthritis [55] and severe periodontitis [56]. It is interesting that transplantation of OPC into arthritic mice strongly inhibits joint inflammation and suppress T-cell proliferation in vitro [50]. These investigations lead to the conclusion that osteoclasts have an important immunomodulatory role [50]. However, many more informations are needed to complete the puzzle of OPC circulating in the blood.

**Endothelial progenitor cells: classical neighborhood cells**

Vasculogenesis is the formation of blood vessels that relays on the differentiation of mesodermal cells to endothelial progenitor cells (EPC) mainly during embryonic development. Angiogenesis is a process of capillary sprouting from preexisting blood vessels which takes place during the lifespan. The intra-embryonic origin of EPC is complex: paraaortic splanchnopleural mesoderm have bipotent cells with the capacity to differentiate to HSC and EPC (hemogenic endothelium), whereas somites produce only EPC [57]. HSC and EPC also arise in avian placenta (allantois) and reach fetal bone marrow via blood [58]. It is a matter of debate if these cells are distinct HSCs and EPCs or placenta generated hemangioblasts, putative bipotent common hematopoietic and endothelial stem cells [58]. The intimate spatial and temporal relationship of HSC and EPC appearance during prenatal development and expression of same molecules (CD34+, Vascular Endothelial Growth Factor Receptor) are the roots of the idea that these cells have the common ancestral cells even in postnatal life.

The first paper that established the idea about the presence of EPCs in the blood of adult humans and mice has been published in 1997 [59]. The source of EPC is considered to be the bone marrow, vascular adventitia and endothelium itself [60]. EPCs have been found among low proliferative, spindle shaped, adherent CD34(+) cell population that after 5 days of specific culturing conditions ingested acetylated low density lipoproteins (acLDL), produced nitric oxide upon acetylcholine stimulation and had a phenotype slightly different in comparison to the originally seeded cell population [59]. Asahara and coworkers [59] also provided evidence that after acute vascular injury, EPCs substantially contribute to the regeneration or repair of vascular structures in injured/ischemic tissues. Recently a more precise molecular and functional sorting of peripheral blood mononuclear cells identified a small fraction of cells (CD146+, CD34+, CD31+, CD45-, CD133-) named Endothelial Colony-Forming Cells (ECFCs) that have robust proliferative potential and may incorporate into perfused vessels in vivo suggesting their true progenitor nature [60]. It is interesting
to note that pro-angiogenic, low proliferative, blood derived monocytes, or other hemopoietic cell subsets endowed with plasticity inherent to mesodermal cell lineage, could transitionally express endothelial phenotype, but without permanent incorporation into the newly formed vessels [61,62]. One should keep in mind that plasticity also depends on culturing conditions and that these conditions influence the phenotype and probably the function of isolated cells.

The view that many pathological conditions could benefit from the inhibition or stimulation of vasculogenesis and angiogenesis was supported by multiple investigations [63-65]. However, some apparently contradictory findings have marked EPC research. Initially, blood born EPCs were seen as protectors of atherosclerotic vessels as they have the ability to replace damaged endothelial cells [66]. Some recent findings demonstrate that adult human peripheral blood contains EPCs identified to co-express osteoblastic surface markers [67]. These “distorted” EPCs are recruited to the injured vascular tissue and contribute to calcification during atherosclerotic processes [67]. Based on this research, down-regulation of the osteogenic phenotype in patients with particular disease prone state is envisaged [68]. Interestingly, EPCs have been reported to easily trans-differentiate to fibroblast and substantially contribute to cardiac fibrosis [69]. Altogether, it seems that EPCs possess high plasticity and potentially are involved in both, beneficial and pathologic tissue response to injury.

Peripheral blood EPCs have not gained attention in veterinary medicine, but large animal models are interesting for preclinical testing of EPC therapeutic potential in various pathological conditions. Although it is estimated that dogs, pigs and sheep are reliable pre-clinical models of ischemic heart disease, their use is not common [70]. One of the rare studies was designed to evaluate the best injection modality for improvement of EPC retention in the myocardium after provoked myocardial infarction in dogs [71]. The other one, designed as a pre-clinical testing in pigs, evaluated implantable cardiovascular devices that should be re-endothelialized with autologous EPCs prior to implantation [72]. These examples underline that large animals are interesting as a model for stem/progenitor cell therapy, with respect to replacement, refinement and reduction of animals in research. On the other side, pets are increasingly becoming a target for stem cells therapy, calling for further research in this area in veterinary medicine.

**Mesenchymal stem cells: non expected guests in unusual place**

MSCs, like HSCs, derived from the mesodermal cell layer and during postnatal life reside within the bone marrow and other connective tissues. In opposition to HSCs that proliferate in suspension cultures, MSCs are adherent to plastic and ECM components. In serial articles published during the seventh and eight decade of the twentieth century, Alexander Friedenstein demonstrated the existence of skeletal tissue stem cells in the bone marrow [73-75] which later on were named mesenchymal stem cells [76]. Friedenstein and coworkers [75] isolated bone marrow stromal cells
responsible for in vivo transfer of the hematopoietic tissues microenvironment. They also demonstrated their clonal nature in vitro and called these cells Colony Forming Unit – Fibroblast (CFU-F) [74]. Their osteogenic and chondrogenic capacity has been demonstrated by the same group [73,74]. Another interesting phenomenon, reported in specific culture conditions, is MSCs immunomodulatory and anti-inflammatory capacity, that could be beneficial to the patient suffering of otherwise detrimental inflammation [9]. Although in vitro characteristics of MSCs are well know, their in vivo localisation and their exact roles in the steady-state are still a matter of debate and exciting field of research.

Generally, skeletal tissues, like bone and cartilage, were thought to regenerate or repair exclusively through proliferation and differentiation of MSC residing in the specific tissue niches, migrating locally, independent of blood flow. Surprisingly for adherent cell type, MSC were detected in adult peripheral and cord blood. First article demonstrating presence of CFU-F in the culture of nucleated blood cells was published by Friedenstein’s group [77]. Afterwards, the presence of adherent stromal cells in the peripheral blood with the phenotype pointing to their non hematopoietic nature (CD14-, CD34-, collagen type I, III and VI and ICAM (CD54) and VCAM (CD106), CD105 and CD73-) was confirmed in breast cancer patients subjected to G-CSF mobilization protocol [78]. Although some authors have not been able to recover MSCs from human peripheral blood [79, 80], others supported the finding that MSCs circulate even in the steady-state. In the peripheral blood mononuclear cell fraction, containing mostly monocytes, on a sample of 100 donors, MSC were found at a frequency of 0.3-0.7% and their osteogenic and adipogenic potential was demonstrated [81]. In particular, the interest to examine different animal models was highlighted in research demonstrating that circulating MSCs are more frequent among rodents comparing to man [82] and that specifically peripheral blood of guinea pigs harbor stromal progenitors or precursors that are exclusively chondrogenic [83]. If these circulating chondrogenic progenitors could home to cartilage, they might contribute to the high ability of articular cartilage self-repair in guinea pigs [83]. Except peripheral blood, cord blood is also a source of undifferentiated stromal cells. However, cord blood is heterogeneous in regard to stem cell content and expression of pluripotency markers (Sox2 and Nanog4) [84]. Only large volumes of cord blood contain enough MSC to establish in vitro culture, making overall efficiency of cord blood MSC isolation quite low [84].

Isolation and culturing of peripheral blood MSCs in domestic animals was quite successful. Dog peripheral blood MSC were isolated from 20mL of heparinized blood and were seeded in adherent culture supplemented with IL-6 [85]. After several passages, adherent cells where CD34-/low, osteocalcin+ [85]. In the same experiment [85], autotransplantation of GFP transfected adherent cells was done after total body irradiation. Fifteen weeks after transplantation, GFP was expressed in osteoblasts lining the bone and small number of circulating mature blood cells, indicating MSC engraftment in the bone marrow, differentiation toward osteoblasts and egression of
one subset of cells into the peripheral blood [85]. More recently, canine cord blood MSCs were used to improve osteointegration between the dental implant and the walls of the alveolar bone [86]. Their osteogenic potential was demonstrated to be high [87], as well as the potential for regeneration/repair of spinal cord after injury [88,89]. This later observation could further be explained with the existence of a small subset of cord blood MSCs that express pluripotent stem cell markers (Oct4, Nanog, Sox 2) and possess an inherent neurogenic potential [84].

In horses, peripheral blood stromal/adherent cells were first isolated under steady state conditions in 2006, but with poor in vitro performances concerning differentiation potential [90]. Afterwards, an optimized protocol has led to the establishment of peripheral blood MSCs with trilineage differentiation potential [91]. Equine cord blood MSCs were isolated with very low frequencies - one to five primary colonies per sample, with trilineage potential, but no phenotypisation has been done [92]. In a case control study, peripheral blood mononuclear cells, conditioned for 72h with M-CSF and separated based on CD90 and CD117 expression, were successfully used for therapy of superficial digital flexor tendon injuries in three horses [93]. In another study, safety of intravenous injection of allogenic peripheral blood MSC was evaluated on 291 horses and no adverse reactions were found either during short or long term (one year) monitoring [94]. It is surprising that only these five articles focused peripheral and cord blood MSCs in horses as this species seems to be the most frequently targeted for MSC therapy. This therapy is simply called „stem cell therapy“ and expands in an uncontrolled manner, with more than 10,000 hints since 2010 only in USA [95].

The possible roles of MSCs recruited into the blood are most probably regeneration and repair of different tissues suffering some kind of damage. One of the experiments trying to clarify MSC role in myocardium regeneration/repair used the myeloablated wild type mice transplanted either with whole bone marrow cells or separated HSCs from GFP transgenic mice [96]. After bone marrow reconstitution, myocardium infarcts have been provoked and HSC have been G-CSF mobilized. After 8 weeks, animals rescued with whole bone marrow had an important number of GFP cardiomyocytes, while animals rescued with HSCs did not have GFP positive cells in the heart [96]. This experiment demonstrated that probably MSCs could regenerate myocardial tissue and that their source is the bone marrow, although a role of other SPCs could not be excluded. On the contrary to this beneficial effect, MSC recruited to the blood under influence of transforming growth factor β1 (TGF-β1) released from injured arteries, homed in injured tissue and contributed to osteogenic vascular calcification [14].

Concerning all stated, peripheral and cord blood MSCs seem to be important for veterinary medicine. Moreover, if not an artifact, easy isolation of MSCs from the animal blood could ameliorate research in this area to be further translated to human medicine.
**Circulating fibrocyte: the cell in between**

Historically, the nomenclature “fibrocyte” was reserved for sessile connective tissue cells that do not have an obvious synthetic activity when compared to fibroblasts. Also, the origin of fibrocytes/fibroblasts was believed to be uniquely mesenchymal. First data reporting on the existence of circulating fibrocytes (fibroblast and monocyte) provided evidence that one part of adherent blood cells co-express monocyte (CD14+, CD11+), pan-leukocyte (CD45+) and hematopoietic stem and progenitor cell markers (CD34+) together with markers of non-differentiated and differentiated mesenchymal cells: pro-collagen type I and vimentin. These cells comprise 0.1-0.5% of the peripheral blood mononuclear cell fraction [97]. These first experiments postulated that fibrocytes derive from a radioresistant bone marrow stromal population (hematopoetic cells are radiosensitive) that is mobilized to blood and homes to the site of tissue injury, undergoing differentiation to fibroblast-like cell thus playing a role in scar formation [97]. Further evidence advocated hematopoietic origin of fibrocytes due to expression of the major histocompatibility complex class I and class II, the co-stimulatory molecules CD80 and CD86 and a role in antigen presentation, typical for myeloid cell lineages [98]. A number of studies, using transplantation of GFP+ HSC into GFP- recipient mice, delineated number of tissues/locations (kidney, heart, inner ear, brain microglia) with GFP+ fibroblasts or myofibroblasts after intervention [3]. The most recent study conducted on mice expressing RFP (red fluorescent protein) in non hematopoetic cells and GFP in hematopoietic cells, demonstrated that two distinct hematopoietic cells (one CD45+ and other CD45-), mobilized from the bone marrow, transitionally depose ECM at the wound site disappearing after wound healing [99].

Circulating fibrocytes gained attention because of their positive impact to wound healing through deposition of ECM, secretion of pro-angiogenic and pro-inflammatory cytokines and antigen presentation [98,100]. Their own recruitment to wounds or sites of chronic inflammation is mediated through the expression of multiple chemokine receptors [33,101,102]. Research done in the last 20 years, accumulated evidence that circulating, bone marrow derived fibrocytes, play an important role in pathological fibrosis that could affect different organs like the lung, liver, myocardium, kidneys and bone marrow itself [103]. Inhibition of fibrocyte differentiation in experimental mice and rat models of lung fibrosis led to reduction in fibrotic lesions [104].

Pathological fibrosis is of interest in small animal practice [105-107], as well as in horses [108] and wild animals [109]. Also, using a comparative natural-occurrence disease model approach, pathological fibrosis in large animals was suggested to be interesting for further research in human disorder pathogenesis [110]. Many research articles combine different approaches to highlight some pathological phenomenon related to tissue injury and regeneration [111-113]. Although the interest to unravel mechanisms of pathological fibrosis in veterinary medicine is evident, and possibilities to find a good model to investigate circulating fibrocytes’ nature and function are multiple, these curious cells have not been investigated in large animals, yet.
Enchanting diversity leads to imagination

Except all described cell populations, some investigators report that pericytes [114], vascular smooth muscle progenitor cells [115] and osteogenic precursor cells [116]. Mostly based on Ratajczak and his group research, very small embryonic-like stem cells (VSELs) have been shown to mobilize from the bone marrow to the blood and recruit to the sites of tissue injury [117]. VSELs are able to differentiate into cells of all germ layers [117]. Concerning all different SPCs that could be found in the blood, historical mythes of blood regenerative potentials could be envisaged to be truly possible.

CONCLUSION

The blood, as well as the bone marrow, have highly versatile stem and progenitor cell population that represent the whole armamentarium promptly recruited as a response to tissue injury. In steady-state, re-circulation of HSPCs, MSPCs, EPCs, OPC, fibrocytes, pericytes and VSELs, is probably related to the surveillance of tissue homeostasis. Apparently, during tissue injury, fast recruitment of these potent cells has an effect on the regulation of inflammatory reactions or to injured tissue regeneration. Some circumstances during inflammation probably trigger signaling that distort SPCs to a non desirable functional phenotype that could be detrimental to the patient. The fact that HSPCs are travelling in the blood is used in human medicine for several decades in the protocols for therapy of different pathologies. In veterinary medicine, this field of research just started to be exploited.

Acknowledgment

The author is very grateful to Dr Zoran Ivanović, Director of R&D, Aquitaine-Limousin Branch of French Blood Institute and Dr Tatjana Božić, Professor at Pathophysiology at Faculty of Veterinary Medicine University of Belgrade, for critical reading of this work.

Funding source: This work was supported by a project of the Ministry of Education, Science and Technological Development, Republic of Serbia (No. 175061).

REFERENCES


**KRV JE BOGATA RAZLIČITIM MATIČNIM I PROGENITORSKIM ĆELIJAMA POREKLOM OD MEZODERMA**

KOVAČEVIĆ FILIPOVIĆ Milica

Ispitivanja krvi i koštane srži se sistematski sprovode duže od sto godina, ali su ova tkiva i dalje izvor novih podataka od značaja za humanu i veterinarsku medicinu. Krvlju cirkulišu različite zrele čelije kao što su eritrociti, trombociti i granulociti, ali i mali broj nediferenciranih čelija mezodermalnog porekla: hematopoteske i mezenhimske matične čelije i čelije progenitori, progenitori endotelnih čelija i jako male čelije nalik embrionalnim. Kod odraslih organizama, koštana srž je izvor praktično svih čelija koje se mogu naći u krvi. Mobilizacija matičnih čelija i čelija progenitora iz koštane srži u krv, i njihov povratak u koštanu srž ili odlazak u druga tkiva je regulisan kompleksnim procesima. Upotreba matičnih čelija hematopoeze i čelija progenitora u humanoj medicini, zasniva se na činjenici da mogu da se mobilisu u krv i da repopulisu koštanu srž proizvodeći zrele čelije krv. U ovom preglednom članku će biti opisane osnovne karakteristike matičnih čelija i čelija progenitora, mehanizmi mobilizacije i prelaska u tkiva. Takođe, značaj činjenice da se u krvi mogu naći različite matične čelije i progenitorske i prekursorske čelije je stvaljena u kontekst njihove primene u humanoj i veterinarskoj medicini.